The NK-1 Receptor Signaling: Distribution and Functional Relevance in the Eye

Demirsoy, İbrahim Halil; Ferrari, Giulio

doi:10.3390/receptors1010006

Cited by 4 publications

(1 citation statement)

References 154 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2 , 16 , 17 Among the multiple neuropeptides involved in this process, substance P (SP) is a relevant actor as it is secreted in large amounts by sensory terminals and promotes pain, angiogenesis, infiltration, and activation of leukocytes. 18 , 19 Recent studies have shown that SP secretion in the tear fluid is increased following laser-assisted in situ keratomileusis (LASIK) surgery and is associated with the development of dry eye symptoms. 20 – 22 Moreover, it has been demonstrated that tear levels of SP are higher in symptomatic contact lenses wearers, and in patients with DED wearing soft contact lens, and, more generally, in patients affected with severe ocular surface inflammation.…”

Section: Introductionmentioning

confidence: 99%

Aprepitant Restores Corneal Sensitivity and Reduces Pain in DED

Bonelli,

Campestre,

Lasagni Vitar

et al. 2024

Trans. Vis. Sci. Tech.

Self Cite

View full text Add to dashboard Cite

Purpose This study aims to assess the efficacy of two aprepitant formulations (X1 and X2), in a preclinical model of dry eye disease (DED) induced by benzalkonium chloride (BAK). Methods Two aprepitant formulations were tested on 7 to 8-week-old male mice for their efficacy. In vivo corneal fluorescein staining assessed epithelial damage as the primary end point on days 0, 3, 5, 7, 9, 12, and 14 using slit-lamp microscopy. The DED model was induced with 0.2% BAK twice daily for the first week and once daily for the next week. Mice were randomly assigned to 5 treatment groups: Aprepitant X1 ( n = 10) and X2 ( n = 10) formulation, 2 mg/mL dexamethasone ( n = 10), control vehicle X ( n = 10), 0.2% hyaluronic acid ( n = 10), or no treatment ( n = 10). Eye wiping, phenol red, and Cochet Bonnet tests assessed ocular pain, tear fluid secretion, and nerve function. After 7 days, the mice were euthanized to quantify leukocyte infiltration and corneal nerve density. Results Topical aprepitant X1 reduced BAK-induced corneal damage and pain compared to gel vehicle X ( P = 0.007) and dexamethasone ( P = 0.021). Aprepitant X1 and X2 improved corneal sensitivity versus gel vehicle X and dexamethasone ( P < 0.001). Aprepitant X1 reduced leukocyte infiltration ( P < 0.05) and enhanced corneal nerve density ( P < 0.001). Tear fluid secretion remained statistically unchanged in both the X1 and X2 groups. Conclusions Aprepitant formulation X1 reduced pain, improved corneal sensitivity and nerve density, ameliorated epitheliopathy, and reduced leukocyte infiltration in male mouse corneas. Translational Relevance Aprepitant emerges as a safe, promising therapeutic prospect for the amelioration of DED's associated symptoms.

show abstract